Etira Founder’s Scientific Journey Highlighted

San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio. He…

Etira CEO Featured In Clinical Leader for R&D Efficiency

Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…

Progress in ERX-315 Phase 1 Clinical Trial

Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1…

Etira Expands Clinical Trial Sites

Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South…

Research on Etira drugs win awards at AACR 2025

Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…

Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025

Chicago, IL - April 23, 2025: Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…

Second site activated for ERX-315 trial

Adelaide, Australia – March 17, 2025:  Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research…

ERX-315 Phase 1 Clinical Trial Update

Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…

Dr. Raj appointed as Etira Chief Medical Officer

Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…

First patient dosed in ERX-315-101 Clinical Trial

Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC)  in Sydney, Australia.…